Novartis and BioAge Labs Forge $550M Collaboration to Develop Novel Anti-Aging Therapeutics

Dec 19, 2024 08:05 CST Updated 08:05

BioAge

Drug Discovery Platform Developer

Novartis

Drug Development and Manufacturing

December 18,California, BioAge Labs, Inc., a clinical-stage biopharmaceutical company developing therapeutic candidates for metabolic diseases by targeting the biology of human aging, announced a multi-year research collaboration with Novartis. The collaboration aims to identify and validate multiple novel therapeutic drug targets by studying the biological mechanisms underlying aging-related diseases and the beneficial effects mediated by physical exercise.

Under the terms of the agreement, BioAge will receive an upfront payment and research funding of up to $20 million, as well as long-term research, development, and commercial milestones of up to $530 million in the future.Novartis and BioAge are both entitled to advance new targets discovered through the collaboration and are eligible for reciprocal success milestones and tiered royalties.

Kristen Fortney, Chief Executive Officer and Co-Founder of BioAge, stated:"Our platform is built on extensive longitudinal human lifespan data, enabling us to identify promising therapeutic pathways with significant potential to improve health outcomes. The collaboration with Novartis demonstrates the value of our platform and expands our ability to discover and develop new targets based on data-driven insights."

This collaboration will leverage BioAge's extensive proprietary human lifespan datasets and Novartis' expertise in exercise biology. BioAge's proprietary discovery platform is based on exclusive access to longitudinal human aging cohorts spanning up to 50 years, integrating detailed health records and functional measurements. Applying advanced analytics and machine learning techniques to this rich dataset enables BioAge to identify determinants of healthspan, providing an engine for therapeutic discovery and development.

Michaela Kneissel, Global Head of Aging and Regenerative Medicine Diseases at Novartis Biomedical Research, stated:"We are excited to partner with BioAge, combining their human lifespan data with our scientific expertise in the biology of physical exercise to uncover new therapeutic targets." "By exploring the intersection between the biology of human aging and the biological drivers behind the beneficial effects of physical exercise, our goal is to propose new treatments for age-related diseases."

Peng Leong, Ph.D., CBO and Head of Brain Aging at BioAge, said:"The collaboration between Novartis and BioAge underscores the growing recognition that unraveling the biology of aging is a powerful approach to treating disease. This partnership represents an important opportunity to accelerate our development of a broad portfolio of transformative therapies targeting novel mechanisms identified by our platform, significantly expanding our therapeutic reach and benefiting patients across multiple indications."

Follow the official account below to see the world!